Why the study?
Intensively treated SPRINT participants had fewer primary cardiovascular events and lower mortality, but 38% experienced serious adverse events; the relationship between serious adverse events and cardiovascular events was unknown.
Is the occurrence of serious adverse events associated with primary cardiovascular composite endpoints and baseline ASCVD risk in participants of the SPRINT trial?
Is the occurrence of serious adverse events associated with primary cardiovascular composite endpoints and baseline ASCVD risk in participants of the SPRINT trial?
Answers are grounded in this paper and cite their sources.
Serious adverse events in the SPRINT trial were strongly clustered with the occurrence of primary cardiovascular events and baseline ASCVD risk, rather than being primarily driven by intensive treatment itself.
BACKGROUND: Intensively treated participants in the SPRINT study experienced fewer primary cardiovascular composite study endpoints (CVD events) and lower mortality, although 38% of participants experienced a serious adverse event (SAE). The relationship of SAEs with CVD events is unknown. METHODS: CVD events were defined as either myocardial infarction, acute coronary syndrome, decompensated heart failure, stroke, or death from cardiovascular causes. Cox models were utilized to understand the occurrence of SAEs with CVD events according to baseline atherosclerotic cardiovascular disease (ASCVD) risk. RESULTS: SAEs occurred in 96% of those experiencing a CVD event but only in 34% (P < 0.001) of those not experiencing a CVD event. Occurrence of SAEs monotonically increased across the range of baseline ASCVD risk being approximately twice as great in the highest compared with the lowest risk category. SAE occurrence was strongly associated with ASCVD risk but was similar within risk groups across treatment arms. In adjusted Cox models, experiencing a CVD event was the strongest predictor of SAEs in all risk groups. By the end of year 1, the hazard ratios for the low, middle, and high ASCVD risk tertiles, and baseline clinical CVD group were 2.56 (95% CI = 1.39-4.71); 2.52 (1.63-3.89); 3.61 (2.79-4.68); 1.86 (1.37-2.54), respectively-a trend observed in subsequent years until study end. Intensive treatment independently predicted SAEs only in the second ASVCD risk tertile. CONCLUSIONS: The occurrence of SAEs is multifactorial and mostly related to prerandomization patient characteristics, most prominently ASCVD risk, which, in turn, relates to in-study CVD events.
No takes yet. Share an insight, caveat, or question.
Botchway et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: